TREATMENT OF RSV WITH COMBINATION PRODUCT

The present invention is directed to the combination of the RSV inhibiting Compound A, i.e. 3-({5-chloro-1-[3-(methylsulfonyl)propyl]-1H-indol-2-yl}methyl)-1-(2,2,2-trifluoroethyl)- 1,3-dihydro-2H-imidazo[4,5-c]pyridin-2-one, and the RSV inhibiting Compound B, i.e. (1S,2S)-2-[4-[7-cyclopropyl-5-[(1R...

Full description

Saved in:
Bibliographic Details
Main Authors ROYMANS DIRK ANDRE EMMY, GOEYVAERTS NELE ISA E, KOUL ANIL, YSEBAERT NINA
Format Patent
LanguageChinese
English
Published 04.08.2020
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The present invention is directed to the combination of the RSV inhibiting Compound A, i.e. 3-({5-chloro-1-[3-(methylsulfonyl)propyl]-1H-indol-2-yl}methyl)-1-(2,2,2-trifluoroethyl)- 1,3-dihydro-2H-imidazo[4,5-c]pyridin-2-one, and the RSV inhibiting Compound B, i.e. (1S,2S)-2-[4-[7-cyclopropyl-5-[(1R)-1-methyl-3,4-dihydro-1H-isoquinoline-2- carbonyl]pyrazolo[1,5-a]pyrimidin-2-yl]-3-fluoro-phenyl]cyclopropanecarboxylic acid for treating or ameliorating RSV infection. The invention further relates to the combination product of Compound A and Compound B, a pharmaceutical product comprising Compound A and Compound B, the use of the combination of Compound A and Compound B - or the pharmaceutical product comprising Compound A and Compound B - for the treatment of RSV infection, and a method of treating or ameliorating RSV infection in a subject in need thereof comprising administering the combination of Compound A and Compound B in an effective amount to said subject. 本发明涉及RSV抑制化合物A,即3-({5-氯-1-[3-(甲基磺酰基)丙基]-1H-吲哚-2
Bibliography:Application Number: CN201880078571